Amyotrofik Lateral Sklerozda Semptom Yönetimine Genel Bakış

Yıl 2021, Cilt: 5 Sayı: 2, 354 - 360, 29.05.2021

Duygu Akbaş Ayfer Karadakovan

https://doi.org/10.46237/amusbfd.757630

Öz

Amyotrofik Lateral Skleroz (ALS), ortalama 2–5 yıl sağkalım gösteren ilerleyici bir motor nöron hastalığıdır. Uygulanan tedaviler sadece hastalığın ilerlemesini yavaşlatmaya yardımcı olmaktadır. Tedavideki bu eksiklikten dolayı ALS'nin kliniklerde multidisipliner semptom temelli yönetimi, hasta için en önemli güncel tedavi stratejisi olmaya devam etmektedir. Bu anlamda hemşireler ALS'nin klinik yönetiminde ekibin faaliyetlerini kontrol etmede, tedaviyi kolaylaştırmada, aile üyelerine bilinçli bakım uygulamalarında rehberlik etmede ve yaşam sonu destek aşamasında kritik bir rol oynar.

Anahtar Kelimeler

Amyotrofik lateral skleroz, semptom, semptom yönetimi, hemşirelik

Destekleyen Kurum

destekleyen kurum ve kuruluş yoktur

Overview of Symptom Management in Amyotrophic Lateral Sclerosis

Öz

Amyotrophic Lateral Sclerosis (ALS) is a progressive motor neuron disease with an average survival of 2–5 years. The treatments applied only help slow the progression of the disease. Due to this deficiency in treatment, multidisciplinary symptom-based management of ALS in clinics continues to be the most important current treatment strategy for the patient. In this sense, nurses play a critical role in the clinical management of ALS in controlling the team's activities, facilitating treatment, guiding family members in conscious care practices, and in the end-of-life support phase.

Anahtar Kelimeler

Amyotrophic lateral sclerosis, symptom, symptom management, nursing

Kaynakça

• 1. Handy, C. R., Krudy, C., Boulis, N., & Federici, T. (2011) Pain in amyotrophic lateral sclerosis: a neglected aspect of disease. Neurology research international, (Electronic Journal) 6(s3): 1-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135011/pdf/NRI2011-403808. (Erişim Tarihi: 20 Mart 2020).
• 2. Hulisz, D. (2018). Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care, 24(15), 320-326.
• 3. Chiò, A., Mora, G., & Lauria, G. (2017). Pain in amyotrophic lateral sclerosis. Lancet Neurol, 16(2), 144-157.
• 4. Mehta, P., Horton, K., Kasarskis, E. J., Tessaro, E., Eisenberg, M. S., Laird, S., et.al. (2017). CDC grand rounds: national amyotrophic lateral sclerosis (als) registry ımpact, challenges, and future directions, US Department of Health and Human Services/Centers for Disease Control and Prevention, 66(50), 1379–1382.
• 5. Wang, M. D., Little, J., Gomes, J., Cashman, N. R., & Krewski, D. (2017). Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology, (61), 101-130.
• 6. Zarei, S., Carr, K., Reiley. L., Diaz K., Guerra O., Fernandez, P., et al. (2015). A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology İnternational, 11(6)1, 171.
• 7. Hardiman, O., Berg, L. H., & Kiernan, M. C. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 7(11), 639-649.
• 8. Capozzella, A., Sacco, C., Chighine, A., Scala, B., Casale, T.,et al.(2014). Work related etiology of amyotrophic lateral sclerosis (ALS): a meta-analysis. Ann Ig. 26(5), 456- 472.
• 9. Bradley, W. G., Borenstein, A. R., Nelson, L. M., Codd G. A., Rosen B. E., Stommel E. A., et al.(2013). Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph Lateral Scler Frontotemporal Degener, 14(5-6), 325-333.
• 10. Jackson, C. E., McVey, A. L., Rudnicki, S., Dimachkie, M. M., & Barohn, R. J. (2015). Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin. ,33(4),889-908.
• 11. Hobson, E. V., & McDermott, C. J. (2016). Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol, 12(9), 526-538.
• 12. Ahmed, R. M., Newcombe, R. E., Piper, A. J., Lewis, S. J., Yee B. J., Kiernan B. C., et al. (2016). Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med Rev. (26), 33-42.
• 13. Pinto, S., & Carvalho, Md. (2014). Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegenerative Disease Management, 4(1), 83-102.
• 14. Alankaya, N. (2012). Amiyotrofik lateral skleroz ve hemşirelik yönetimi. Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi, 2(15), 159-152.
• 15. Roche, J. C., Rojas-Garcia, R., Scott, K. M., Scotton, W., Ellis C. E., Burman, R. ,et al. (2012). A proposed staging system for amyotrophic lateral sclerosis. Brain, 135(3), 847-852.
• 16. Özcan, F., Kaya, A., & Yayla, M. (2016). Amyotrofik lateral skleroz hastalığı ve aile hekiminin rolü. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 3 (3) , 431-435.
• 17. Delpont, B., Beauvais, K., Jacquin-Piques, A., Alavoine, V., Rault, P., Blanc-Labarre, C., et.al. (2018). Clinicalfeatures of pain in amyotrophiclateralsclerosis: A clinicalchallenge. Revue Neurologique,175(1-2), 11-15.
• 18. Kaya, A., Dik, A., Tülek, Z., Alankaya, N., Özakgül, A., Ünalan, P., & İdrisoğlu, H. A. (2015). Amyotrofik Lateral Sklerozlu (ALS) Hastalara Evde Bakım Projesi:“Yaşamak Yetmez, Yaşatmak Da Lazım”.
• 19. Caligari, M., Godi, M., Guglielmetti, S., Franchignoni, F., & Nardone, A. (2013). Eye tracking communication devices in amyotrophic lateral sclerosis: impact on disability and quality of life. Amyotroph Lateral Scler Frontotemporal Degener, 14(7-8), 546-552.
• 20. Londral, A., Pinto, A., Pinto, S., Azevedo, L., & De Carvalho, M.(2015). Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. Muscle Nerve. 2(6), 933-941.
• 21. Vacca, V. M. Jr. (2020). Amyotrophic lateral sclerosis: Nursing care and considerations. Nursing,50(6), 32-39.